PAK4 and non-Hodgkin lymphoma: So far, just the KPT-9274, a PAK4 and NAMPT dual inhibitor, is ongoing in phase I clinical trials (NCT02702492 and NCT04281420) for solid tumors and non-Hodgkin’s lymphoma (NHL) (Abu Aboud et al., 2016; Li et al., 2019; Cordover et al., 2020).